PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502
Discontinued
Reference number: GID-TA10402
Following on from information provided to NICE by the company in May 2020 the appraisal of PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer [ID1502] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.